The DOI matches its Crossref record; 177 of the 177 references it cites were found in a registry or an index.
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Open accessAbstract
Natural killer (NK) cells play a major role in cancer immunotherapies that involve tumor-antigen targeting by monoclonal antibodies (mAbs). NK cells express a variety of activating and inhibitory receptors that serve to regulate the function and activity of the cells. In the context of targeting cells, NK cells can be "specifically activated" through certain Fc receptors that are expressed on their cell surface. NK cells can express FcγRIIIA and/or FcγRIIC, which can bind to the Fc portion of immunoglobulins, transmitting activating signals within NK cells. Once activated through Fc receptors by antibodies bound to target cells, NK cells are able to lyse target cells without priming, and secrete cytokines like interferon gamma to recruit adaptive immune cells. This antibody-dependent cell-mediated cytotoxicity (ADCC) of tumor cells is utilized in the treatment of various cancers overexpressing unique antigens, such as neuroblastoma, breast cancer, B cell lymphoma, and others. NK cells also express a family of receptors called killer immunoglobulin-like receptors (KIRs), which regulate the function and response of NK cells toward target cells through their interaction with their cognate ligands that are expressed on tumor cells. Genetic polymorphisms in KIR and KIR-ligands, as well as FcγRs may influence NK cell responsiveness in conjunction with mAb immunotherapies. This review focuses on current therapeutic mAbs, different strategies to augment the anti-tumor efficacy of ADCC, and genotypic factors that may influence patient responses to antibody-dependent immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“In xenograft mouse models of B-cell lymphoma, the anti-tumor effect of rituximab was greatly reduced in FcRγ−/− nude mice (82), or in mice treated with FcγR block (92).”
BackgroundIn search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687 · cited 1×
“If the target cell is missing the expression of the HLA ligand for the inhibitory receptors on that NK cell, and expresses ligands for the activating receptors, the interaction could lead to NK cell activation due to lack of inhibitory signals (“missing-self ” hypothesis) (11, 12).”
BackgroundDrug delivery with carbon nanotubes for in vivo cancer treatment
Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,286
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Cancer Research Communications
(2021) · doi:10.1158/1078-0432 · Cited by 1,532
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Licensing of natural killer cells by host major histocompatibility complex class I molecules
Kim, S., Poursine-Laurent, J., Truscott, S. M., Lybarger, L., Song, Y.-J., Yang, L., French, A. R., Sunwoo, J. B., Lemieux, S., Hansen, T. H., et al. (2005) · Nature · doi:10.1038/nature03847 · Cited by 1,340
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Human NK Cell Education by Inhibitory Receptors for MHC Class I
Anfossi, N., André, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.013 · Cited by 1,211
MHC class I molecules and kirs in human history, health and survival
Parham, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1570 · Cited by 1,203
Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., & Caligiuri, M. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1395 · Cited by 1,092
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
CD56bright natural killer (NK) cells: an important NK cell subset
Poli, A., Michel, T., Thérésine, M., Andrès, E., Hentges, F., & Zimmer, J. (2009) · Immunology · doi:10.1111/j.1365-2567.2008.03027.x · Cited by 977
Bryceson, Y. T., March, M. E., Ljunggren, H.-G., & Long, E. O. (2006) · Blood · doi:10.1182/blood-2005-04-1351 · Cited by 863
Koene, H. R., Kleijer, M., Algra, J., Roos, D., E.G.Kr. von dem Borne, A., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 794
Activation of NK cell cytotoxicity
Smyth, M. J., Cretney, E., Kelly, J. M., Westwood, J. A., Street, S. E. A., Yagita, H., Takeda, K., Dommelen, S. L. H. V., Degli-Esposti, M. A., & Hayakawa, Y. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.034 · Cited by 714
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
NK cell development, homeostasis and function: parallels with CD8+ T cells
Sun, J. C., & Lanier, L. L. (2011) · Nature Reviews Immunology · doi:10.1038/nri3044 · Cited by 700
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Cerwenka, A., Baron, J. L., & Lanier, L. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201238598 · Cited by 606
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 595
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
Huntington, N. D., Legrand, N., Alves, N. L., Jaron, B., Weijer, K., Plet, A., Corcuff, E., Mortier, E., Jacques, Y., Spits, H., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082013 · Cited by 577
Garnett, C. T., Palena, C., Chakarborty, M., Tsang, K.-Y., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1525 · Cited by 557
Romee, R., Foley, B., Lenvik, T., Wang, Y., Zhang, B., Ankarlo, D., Luo, X., Cooley, S., Verneris, M., Walcheck, B., et al. (2013) · Blood · doi:10.1182/blood-2012-04-425397 · Cited by 552
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521 · cited 1×
“In addition, in mCRC patients treated with cetuximab and irinotecan, those who have higher affinity FcγR polymorphisms had longer progression-free survival (45, 86).”
BackgroundYawata, M., Yawata, N., Draghi, M., Little, A.-M., Partheniou, F., & Parham, P. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051884 · Cited by 520
Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482
Hsu, K. C., Keever-Taylor, C. A., Wilton, A., Pinto, C., Heller, G., Arkun, K., O'Reilly, R. J., Horowitz, M. M., & Dupont, B. (2005) · Blood · doi:10.1182/blood-2004-12-4825 · Cited by 473
Chakraborty, M., Abrams, S. I., Coleman, C. N., Camphausen, K., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0073 · Cited by 435
Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435
Cooley, S., Trachtenberg, E., Bergemann, T. L., Saeteurn, K., Klein, J., Le, C. T., Marsh, S. G. E., Guethlein, L. A., Parham, P., Miller, J. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-171926 · Cited by 434
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., & Klingemann, H. (2008) · Cytotherapy · doi:10.1080/14653240802301872 · Cited by 434
IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
Marks-Konczalik, J., Dubois, S., Losi, J. M., Sabzevari, H., Yamada, N., Feigenbaum, L., Waldmann, T. A., & Tagaya, Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200363097 · Cited by 433
HLA-C–Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1
Venstrom, J. M., Pittari, G., Gooley, T. A., Chewning, J. H., Spellman, S., Haagenson, M., Gallagher, M. M., Malkki, M., Petersdorf, E., Dupont, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200503 · Cited by 429
Cheung, N. K., Lazarus, H., Miraldi, F. D., Abramowsky, C. R., Kallick, S., Saarinen, U. M., Spitzer, T., Strandjord, S. E., Coccia, P. F., & Berger, N. A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.9.1430 · Cited by 417
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 415
Recognition of peptide–MHC class I complexes by activating killer immunoglobulin-like receptors
Stewart, C. A., Laugier-Anfossi, F., Vély, F., Saulquin, X., Riedmuller, J., Tisserant, A., Gauthier, L., Romagné, F., Ferracci, G., Arosa, F. A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503594102 · Cited by 406
Combining radiotherapy and immunotherapy: A revived partnership
Demaria, S., Bhardwaj, N., McBride, W. H., & Formenti, S. C. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.06.032 · Cited by 375
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372
Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1182 · Cited by 366
Nature's TRAIL—On a Path to Cancer Immunotherapy
Smyth, M. J., Takeda, K., Hayakawa, Y., Peschon, J. J., van den Brink, M. R. M., & Yagita, H. (2003) · Immunity · doi:10.1016/s1074-7613(02)00502-2 · Cited by 366
Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid).
Dorshkind, K., Pollack, S. B., Bosma, M. J., & Phillips, R. A. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.6.3798 · Cited by 346
De Maria, A., Bozzano, F., Cantoni, C., & Moretta, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012356108 · Cited by 344
Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614636 · Cited by 337
Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells.
Cheung, N. V., Saarinen, U. M., Neely, J. E., et al. (1985) · PubMed · Cited by 322
Srivastava, R. M., Lee, S. C., Andrade Filho, P. A., Lord, C. A., Jie, H.-B., Davidson, H. C., López-Albaitero, A., Gibson, S. P., Gooding, W. E., Ferrone, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2426 · Cited by 318
Mortier, E., Quéméner, A., Vusio, P., Lorenzen, I., Boublik, Y., Grötzinger, J., Plet, A., & Jacques, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508624200 · Cited by 308
Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305
Berg, M., Lundqvist, A., McCoy, P., Samsel, L., Fan, Y., Tawab, A., & Childs, R. (2009) · Cytotherapy · doi:10.1080/14653240902807034 · Cited by 304
Wang, R., Jaw, J. J., Stutzman, N. C., Zou, Z., & Sun, P. D. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0611308 · Cited by 301
Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes.
Lanier, L. L., Ruitenberg, J. J., & Phillips, J. H. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.10.3478 · Cited by 299
CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells
Juelke, K., Killig, M., Luetke-Eversloh, M., Parente, E., Gruen, J., Morandi, B., Ferlazzo, G., Thiel, A., Schmitt-Knosalla, I., & Romagnani, C. (2010) · Blood · doi:10.1182/blood-2009-11-253286 · Cited by 286
Impairment of NK Cell Function by NKG2D Modulation in NOD Mice
Ogasawara, K., Hamerman, J. A., Hsin, H., Chikuma, S., Bour-Jordan, H., Chen, T., Pertel, T., Carnaud, C., Bluestone, J. A., & Lanier, L. L. (2003) · Immunity · doi:10.1016/s1074-7613(02)00505-8 · Cited by 276
Gleason, M. K., Ross, J. A., Warlick, E. D., Lund, T. C., Verneris, M. R., Wiernik, A., Spellman, S., Haagenson, M. D., Lenvik, A. J., Litzow, M. R., et al. (2014) · Blood · doi:10.1182/blood-2013-10-533398 · Cited by 266
(1979) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/63.5.1229 · Cited by 263
Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment
Joncker, N. T., Shifrin, N., Delebecque, F., & Raulet, D. H. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100570 · Cited by 259
Burns, L. J., Weisdorf, D. J., DeFor, T. E., Vesole, D. H., Repka, T. L., Blazar, B. R., Burger, S. R., Panoskaltsis-Mortari, A., Keever-Taylor, C. A., Zhang, M.-J., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704086 · Cited by 252
Shusterman, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D., Seeger, R. C., Reynolds, C. P., Kimball, J., Albertini, M. R., Wagner, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8861 · Cited by 248
Mujoo, K., Cheresh, D. A., Yang, H. M., & Reisfeld, R. A. (1987) · PubMed · Cited by 246
Safety and immunologic effects of IL-15 administration in nonhuman primates
Berger, C., Berger, M., Hackman, R. C., Gough, M., Elliott, C., Jensen, M. C., & Riddell, S. R. (2009) · Blood · doi:10.1182/blood-2008-12-189266 · Cited by 244
Gleason, M. K., Verneris, M. R., Todhunter, D. A., Zhang, B., McCullar, V., Zhou, S. X., Panoskaltsis-Mortari, A., Weiner, L. M., Vallera, D. A., & Miller, J. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0692 · Cited by 238
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Tarek, N., Le Luduec, J.-B., Gallagher, M. M., Zheng, J., Venstrom, J. M., Chamberlain, E., Modak, S., Heller, G., Dupont, B., Cheung, N.-K. V., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62749 · Cited by 229
Niwa, R., Hatanaka, S., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A., Yokoi, H., Nakamura, K., & Shitara, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0850 · Cited by 227
Coudert, J. D., Zimmer, J., Tomasello, E., Cebecauer, M., Colonna, M., Vivier, E., & Held, W. (2005) · Blood · doi:10.1182/blood-2005-03-0918 · Cited by 226
Wiernik, A., Foley, B., Zhang, B., Verneris, M. R., Warlick, E., Gleason, M. K., Ross, J. A., Luo, X., Weisdorf, D. J., Walcheck, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0505 · Cited by 226
Elliott, J. M., Wahle, J. A., & Yokoyama, W. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100986 · Cited by 225
Junttila, T. T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3704 · Cited by 221
Handgretinger, R., Anderson, K., Lang, P., Dopfer, R., Klingebiel, T., Schrappe, M., Reuland, P., Gillies, S. D., Reisfeld, R. A., & Niethammer, D. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00413-y · Cited by 213
Kushner, B. H., Kramer, K., & Cheung, N.-K. V. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4189 · Cited by 208
Breunis, W. B., van Mirre, E., Bruin, M., Geissler, J., de Boer, M., Peters, M., Roos, D., de Haas, M., Koene, H. R., & Kuijpers, T. W. (2008) · Blood · doi:10.1182/blood-2007-03-079913 · Cited by 207
Morschhauser, F. A., Cartron, G., Thieblemont, C., Solal-Céligny, P., Haioun, C., Bouabdallah, R., Feugier, P., Bouabdallah, K., Asikanius, E., Lei, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9585 · Cited by 206
Munger, W., Dejoy, S. Q., Jeyaseelan, R., Torley, L. W., Grabstein, K. H., Eisenmann, J., Paxton, R., Cox, T., Wick, M. M., & Kerwar, S. S. (1995) · Cellular Immunology · doi:10.1006/cimm.1995.1216 · Cited by 200
Xu, W., Jones, M., Liu, B., Zhu, X., Johnson, C. B., Edwards, A. C., Kong, L., Jeng, E. K., Han, K., Marcus, W. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2357 · Cited by 198
Waldmann, T. A., Lugli, E., Roederer, M., Perera, L. P., Smedley, J. V., Macallister, R. P., Goldman, C. K., Bryant, B. R., Decker, J. M., Fleisher, T. A., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311456 · Cited by 195
Clinical Cancer Therapy by NK Cells via Antibody‐Dependent Cell‐Mediated Cytotoxicity
Alderson, K. L., & Sondel, P. M. (2011) · BioMed Research International · doi:10.1155/2011/379123 · Cited by 188
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.
Mueller, B. M., Romerdahl, C. A., Gillies, S. D., & Reisfeld, R. A. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.4.1382 · Cited by 186
Delgado, D. C., Hank, J. A., Kolesar, J., Lorentzen, D., Gan, J., Seo, S., Kim, K., Shusterman, S., Gillies, S. D., Reisfeld, R. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2211 · Cited by 179
Continuous engagement of a self-specific activation receptor induces NK cell tolerance
Tripathy, S. K., Keyel, P. A., Yang, L., Pingel, J. T., Cheng, T. P., Schneeberger, A., & Yokoyama, W. M. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072446 · Cited by 176
Carson, W. E., Parihar, R., Lindemann, M. J., Personeni, N., Dierksheide, J. E., Meropol, N. J., Baselga, J. M., & Caligiuri, M. A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<3016::aid-immu3016>3.0.co;2-j · Cited by 175
Radiation and stress-induced apoptosis: A role for Fas/Fas ligand interactions
Reap, E. A., Roof, K., Maynor, K., Borrero, M., Booker, J., & Cohen, P. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5750 · Cited by 173
Colony-stimulating factors for chemotherapy-induced febrile neutropenia
Mhaskar, R., Clark, O. A. C., Lyman, G., Engel Ayer Botrel, T., Morganti Paladini, L., & Djulbegovic, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003039.pub2 · Cited by 172
Divergent and convergent evolution of NK-cell receptors
Barten, R., Torkar, M., Haude, A., Trowsdale, J., & Wilson, M. J. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(00)01802-0 · Cited by 171
Targeted Interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow
Lode, H. N., Xiang, R., Dolman, C. S., Reisfeld, R. A., Varki, N. M., & Gillies, S. D. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.21.1586 · Cited by 168
Navid, F., Sondel, P. M., Barfield, R., Shulkin, B. L., Kaufman, R. A., Allay, J. A., Gan, J., Hutson, P., Seo, S., Kim, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4423 · Cited by 165
Barker, E., Mueller, B. M., Handgretinger, R., Herter, M., Yu, A. L.-T., & Reisfeld, R. A. (1991) · PubMed · Cited by 164
Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B
Breunis, W. B., van Mirre, E., Geissler, J., Laddach, N., Wolbink, G., van der Schoot, E., de Haas, M., de Boer, M., Roos, D., & Kuijpers, T. W. (2009) · Human Mutation · doi:10.1002/humu.20997 · Cited by 162
López-Albaitero, A., Lee, S. C., Morgan, S., Grandis, J. R., Gooding, W. E., Ferrone, S., & Ferris, R. L. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0697-4 · Cited by 160
Cheung, N. V., Guo, H.-F., Hu, J., Tassev, D. V., & Cheung, I. Y. (2012) · OncoImmunology · doi:10.4161/onci.19864 · Cited by 159
Functional and clinical consequences of Fc receptor polymorphic and copy number variants
Bournazos, S., Woof, J. M., Hart, S. P., & Dransfield, I. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03980.x · Cited by 157
Targeting EGFR in Colorectal Cancer
Messersmith, W. A., & Ahnen, D. J. (2008) · New England Journal of Medicine · doi:10.1056/nejme0806778 · Cited by 156
Novel Human Interleukin-15 Agonists
Zhu, X., Marcus, W. D., Xu, W. V., Lee, H.-I., Han, K., Egan, J. O., Yovandich, J. L., Rhode, P. R., & Wong, H. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901244 · Cited by 155
Mujoo, K., Kipps, T. J., Yang, H., et al. (1989) · PubMed · Cited by 155
Klee, G. G. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0921-hama · Cited by 152
Hank, J. A., Robinson, R. R., Surfus, J. E., Mueller, B. M., Reisfeld, R. A., Cheung, N. K., & Sondel, P. M. (1990) · PubMed · Cited by 151
A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a
Handgretinger, R., Baader, P., Dopfer, R. E., et al. (1992) · Cancer Immunology Immunotherapy · doi:10.1007/bf01756188 · Cited by 151
Bessard, A., Solé-Jamault, V., Bouchaud, G., Quéméner, A., & Jacques, Y. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0275 · Cited by 151
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Marsh, S. G. E., Spellman, S. R., Haagenson, M. D., Saeturn, K., Ladner, M. B., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302517 · Cited by 148
Sehn, L. H., Assouline, S. E., Stewart, D. A., Mangel, J. E., Gascoyne, R. D., Fine, G. D., Lasserre, S., Carlile, D. J., & Crump, M. (2012) · Blood · doi:10.1182/blood-2012-02-408773 · Cited by 147
Grzywacz, B. J., Kataria, N., & Verneris, M. R. (2007) · Leukemia · doi:10.1038/sj.leu.2404499 · Cited by 147
Sorkin, L. S., Otto, M., Baldwin, W. M., Vail, E. A., Gillies, S. D., Handgretinger, R., Barfield, R. C., Yu, H. M., & Yu, A. L.-T. (2010) · Pain · doi:10.1016/j.pain.2010.01.024 · Cited by 141
Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer
Imai, M., Landen, C., Ohta, R., Cheung, N. V., & Tomlinson, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1894 · Cited by 139
Reusch, U., Duell, J., Ellwanger, K., Herbrecht, C., Knackmuss, S. H. J., Fucek, I., Eser, M., McAleese, F., Molkenthin, V., Gall, F. L., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1029216 · Cited by 134
Tolerance of NK cells encountering their viral ligand during development
Sun, J. C.-Y., & Lanier, L. L. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072448 · Cited by 125
Moesta, A. K., & Parham, P. (2012) · Front. Immun. · doi:10.3389/fimmu.2012.00336 · Cited by 112
Phenotypic Variation in IgG Receptors by Nonclassical FCGR2C Alleles
van der Heijden, J., Breunis, W. B., Geissler, J., de Boer, M., van den Berg, T. K., & Kuijpers, T. W. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003945 · Cited by 110
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.
Riethmüller, G. (2012) · Europe PMC (PubMed Central) · Cited by 107
Vallera, D. A., Zhang, B., Gleason, M., Oh, S., Weiner, L. M., Kaufman, D. S., McCullar, V., Miller, J. S., & Verneris, M. R. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1329 · Cited by 105
Li, H., Pascal, V., Martin, M. P., Carrington, M. N., & Anderson, S. K. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000254 · Cited by 104
Taylor, R. J., Chan, S., Wood, A., Voskens, C., Wolf, J. S., Lin, W., Chapoval, A. I., Schulze, D. H., Tian, G., & Strome, S. E. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0613-3 · Cited by 103
Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
Repka, T. L., Chiorean, E. G., Gay, J., Herwig, K. E., Kohl, V., Yee, D., & Miller, J. S. (2003) · PubMed · Cited by 102
David, G., Djaoud, Z., Willem, C., Legrand, N., Rettman, P., Gagne, K., Cesbron, A., & Retière, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301580 · Cited by 98
Carlotti, E., Palumbo, G. A., Oldani, E., Tibullo, D., Salmoiraghi, S., Rossi, A., Golay, J., Pulsoni, A., Foà, R., & Rambaldi, A. (2007) · Haematologica · doi:10.3324/haematol.11288 · Cited by 96
Liu, Q., Sun, Y., Rihn, S. J., Nolting, A., Tsoukas, P. N., Jost, S., Cohen, K. W., Walker, B. D., & Alter, G. (2009) · Journal of Virology · doi:10.1128/jvi.02666-08 · Cited by 94
Worland, P. J., Gray, K., Rolfe, P. M., Gray, K., & Ross, M. J. S. (2003) · American Journal of Clinical Pathology · doi:10.1309/y6lpc0lr726l9dx9 · Cited by 93
Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment
Weidle, U. H., Kontermann, R. E., & Brinkmann, U. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.004 · Cited by 89
Advances in bispecific biotherapeutics for the treatment of cancer
May, C., Sapra, P., & Gerber, H. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.011 · Cited by 87
Renner, P., Milazzo, S., Liu, J., Zwahlen, M., Birkmann, J., & Horneber, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007913.pub2 · Cited by 84
Leung, W. H., Handgretinger, R., Iyengar, R. V., Turner, V., Holladay, M. S., & Hale, G. A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603913 · Cited by 81
Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Olson, W. C., Heston, W. D. W., & Rajasekaran, A. K. (2007) · Reviews on Recent Clinical Trials · doi:10.2174/157488707781662724 · Cited by 78
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
Albertini, M. R., Hank, J. A., Gadbaw, B., Kostlevy, J., Haldeman, J., Schalch, H., Gan, J., Kim, K., Eickhoff, J. C., Gillies, S. D., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1286-5 · Cited by 77
Kogon, M. M., Biswas, A., Pearl, D., Carlson, R. W., & Spiegel, D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970715)80:2<317::aid-cncr21>3.0.co;2-w · Cited by 74
Voskens, C., Watanabe, R., Rollins, S., Campana, D., Hasumi, K., & Mann, D. L. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-134 · Cited by 73
Impact of Stromal Sensitivity on Radiation Response of Tumors
Budach, W., Taghian, A. G., Freeman, J., Gioioso, D., & Suit, H. D. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.12.988 · Cited by 72
Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation
Thommesen, J. E., Michaelsen, T. E., Løset, G. Å., Sandlie, I., & Brekke, O. H. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(01)00010-4 · Cited by 71
Moga, E., Álvarez, E., Cantó, E., Vidal, S., Rodríguez-Sánchez, J. L., Sierra, J., & Briones, J. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.012 · Cited by 71
Draghi, M., Yawata, N., Gleimer, M., Yawata, M., Valiante, N., & Parham, P. (2005) · Blood · doi:10.1182/blood-2004-08-3174 · Cited by 71
Ahlgrimm, M., Pfreundschuh, M. G., Kreuz, M., Regitz, E., Preuss, K., & Bittenbring, J. T. (2011) · Blood · doi:10.1182/blood-2011-04-346411 · Cited by 70
Persky, D. O., Dornan, D., Goldman, B. H., Braziel, R. M., Fisher, R. I., LeBlanc, M. L., Maloney, D. G., Press, O. W., Miller, T., & Rimsza, L. M. (2012) · Haematologica · doi:10.3324/haematol.2011.050419 · Cited by 70
Hank, J. A., Surfus, J. E., Gan, J., Jaeger, P., Gillies, S. D., Reisfeld, R. A., & Sondel, P. M. (1996) · PubMed · Cited by 68
Vincent, M., Bessard, A., Cochonneau, D., Teppaz, G., Solé-Jamault, V., Maillasson, M., Birklé, S., Garrigue‐Antar, L., Quéméner, A., & Jacques, Y. (2013) · International Journal of Cancer · doi:10.1002/ijc.28059 · Cited by 67
Re: Impact of Stromal Sensitivity on Radiation Response of Tumors
Budach, W. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.23.1842 · Cited by 67
Ghesquières, H., Cartron, G., Seymour, J. F., Delfau‐Larue, M., Offner, F. C., Soubeyran, P., Perrot, A., Brice, P., Bouabdallah, R., Sonet, A., et al. (2012) · Blood · doi:10.1182/blood-2012-05-431825 · Cited by 66
Monteverde, M., Milano, G. A., Strola, G., Maffi, M., Lattanzio, L., Vivenza, D., Tonissi, F., Merlano, M. C., & Nigro, C. L. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.02.014 · Cited by 65
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
Dahan, L., Norguet, E., Étienne-Grimaldi, M.-C., Formento, J., Gasmi, M., Nanni, I., Gaudart, J., Garcia, S., Ouafik, L., Seitz, J., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-496 · Cited by 64
Bruenke, J., Barbin, K., Kunert, S., Lang, P., Pfeiffer, M. M., Stieglmaier, K., NIETHAMMER, D., Stockmeyer, B., Peipp, M., Repp, R., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05414.x · Cited by 63
Pittari, G., Liu, X.-R., Selvakumar, A., Zhao, Z.-G., Merino, E., Huse, M., Chewning, J., Hsu, K. C., & Dupont, B. (2013) · Journal of Immunology · doi:10.4049/jimmunol.1202120 · Cited by 60
Mitrović, Z., Aurer, I., Radman, I., Ajduković, R., Sertić, J., & Labar, B. (2007) · Haematologica · doi:10.3324/haematol.10327 · Cited by 60
The killer cell inhibitory receptor genomic region on human chromosome 19q13.4.
Dupont, B., Selvakumar, A., & Steffens, U. (1997) · Tissue Antigens · doi:10.1111/j.1399-0039.1997.tb02802.x · Cited by 59
Glorius, P., Baerenwaldt, A., Kellner, C., Staudinger, M., Dechant, M., Stauch, M. B., Beurskens, F. J. M., Parren, P. W. H. I., van de Winkel, J. G. J., Valerius, T., et al. (2012) · Leukemia · doi:10.1038/leu.2012.150 · Cited by 56
Kinder, M., Greenplate, A. R., Strohl, W. R., Jordan, R. E., & Brezski, R. J. (2015) · mAbs · doi:10.1080/19420862.2015.1022692 · Cited by 55
Turini, M., Chames, P., Bruhns, P., Baty, D., & Kerfélec, B. (2014) · Oncotarget · doi:10.18632/oncotarget.2093 · Cited by 54
Du, J., López‐Vergès, S., Pitcher, B. N., Johnson, J. L., Jung, S., Zhou, L., Hsu, K. C., Czuczman, M. S., Cheson, B. D., Kaplan, L., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0158 · Cited by 53
Deng, X., Terunuma, H., Nieda, M., Xiao, W., & Nicol, A. J. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.09.014 · Cited by 47
Zhang, W., Azuma, M., Lurje, G., Gordon, M. A., Yang, D., Pohl, A., Ning, Y., Bohanes, P. O., Gerger, A., Winder, T., et al. (2010) · PubMed · Cited by 47
Kellner, C., Bruenke, J., Horner, H., Schubert, J. E. A., Schwenkert, M., Mentz, K., Barbin, K., Stein, C., Peipp, M., & Stockmeyer, B. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.020 · Cited by 47
Current status of Interleukin-2 therapy in cancer
Tartour, É., Mathiot, C., & Fridman, W. H. (1992) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(92)90005-r · Cited by 46
Étienne-Grimaldi, M.-C., Bennouna, J., Formento, J., Douillard, J.-Y., Francoual, M., Hennebelle, I., Chatelut, É., François, É., Faroux, R., Elhannani, C., et al. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04141.x · Cited by 43
Funakoshi, S., Longo, D. L., & Murphy, W. J. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199603000-00002 · Cited by 41
Functional CD32 Molecules on Human NK Cells
Morel, P. A., Ernst, L. K., & Metes, D. (1999) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199909145704 · Cited by 41
Gubbels, J. A. A., Gadbaw, B., Buhtoiarov, I. N., Horibata, S., Kapur, A., Patel, D., Hank, J. A., Gillies, S. D., Sondel, P. M., Patankar, M. S., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1072-9 · Cited by 40
Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse
Vincent, M., Teppaz, G., Lajoie, L., Solé-Jamault, V., Bessard, A., Maillasson, M., Loisel, S., Béchard, D., Clemenceau, B., Thibault, G., et al. (2014) · mAbs · doi:10.4161/mabs.28699 · Cited by 38
Moga, E., Cantó, E., Vidal, S., Juárez, C., Sierra, J., & Briones, J. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.08.006 · Cited by 37
Ogura, M., Tobinai, K., Hatake, K., et al. (2012) · Cancer Science · doi:10.1111/cas.12040 · Cited by 34
Wattenberg, M. M., Kwilas, A. R., Gameiro, S. R., Dicker, A. P., & Hodge, J. W. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.79 · Cited by 30
de Menezes, D. E. L., Denis-Mize, K. S., Tang, Y., Ye, H., Kunich, J. C., Garrett, E. N., Peng, J., Cousens, L. S., Gelb, A. B., Heise, C. C., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211315.21116.07 · Cited by 30
The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer.
Sugimoto, Y., Hirota, M., Yoshikawa, K., Sumitomo, M., Nakamura, K., Ueda, R., Niwa, R., Suzawa, T., Yamasaki, M., Shitara, K., et al. (2014) · PubMed · Cited by 25
Procházka, V., Papajík, T., Gazdová, J., Divoká, M., Rožmanová, Š., Faber, E., Raida, L., Kučerová, L., Langová, K., Jarošová, M., et al. (2011) · Neoplasma · doi:10.4149/neo_2011_03_263 · Cited by 23
Schubert, I. A., Saul, D., Nowecki, S., Mackensen, A., Fey, G. H., & Oduncu, F. S. (2013) · mAbs · doi:10.4161/mabs.26768 · Cited by 15
In Vivo Binding and Antitumor Activity of Ch 14.18
Kendra, K. L., Malkovska, V., Allen, M., Guzman, J., & Albertini, M. R. (1999) · Journal of Immunotherapy · doi:10.1097/00002371-199909000-00006 · Cited by 14
Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay
Burchard, P. R., Malhotra, S., Kaur, P., & Tsongalis, G. J. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2013.03.002 · Cited by 12
Cited by
CAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 773
NK cell-based cancer immunotherapy: from basic biology to clinical development
Liu, S., Galat, V., Galat4, Y., Lee, Y. K. A., Wainwright, D., & Wu, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01014-w · Cited by 689
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donne, R., & Lujambio, A. (2023) · Hepatology · doi:10.1002/hep.32740 · Cited by 631
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood · doi:10.1182/blood-2017-06-741041 · Cited by 499
Metadata
- Authors
- Wang, W.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2015
- Volume
- 6
- Pages
- 368-368
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W1491394604
- Cited by
- 567
- References
- 177
- FWCI
- 16.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.